SEPN
HEALTHCARESepterna Inc
Live · NASDAQ · May 9, Close
What's Moving SEPN Today?
No stock-specific AI insight has been generated for SEPN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$24.71
Fundamentals
Trading
SEPN News
20 articles- Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Septerna to Present at Bank of America Securities Health Care ConferenceYahoo Finance·May 5, 2026
- Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 4, 2026
- Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of HypoparathyroidismYahoo Finance·Apr 13, 2026
- Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 9, 2026
- Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 9, 2026
- Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)?Yahoo Finance·Mar 3, 2026
- Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategyYahoo Finance·Mar 1, 2026
- Septerna to Present at TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 10, 2026
- Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual MeetingYahoo Finance·Feb 10, 2026
- Assessing Septerna (SEPN) Valuation After Recent Share Price Pullback And One Year 40.63% ReturnYahoo Finance·Jan 10, 2026
- Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal OfficerYahoo Finance·Jan 8, 2026
- Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst callsYahoo Finance·Dec 23, 2025
- Septerna to Present at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 17, 2025
- Septerna to Participate in 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 25, 2025
- Why Septerna (SEPN) Is Up 28.5% After Posting a Surprise Profit and Analyst UpgradesYahoo Finance·Nov 17, 2025
- A Look at Septerna (SEPN) Valuation Following Strong Q3 Sales and Swing to ProfitabilityYahoo Finance·Nov 15, 2025
- Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 10, 2025
- Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 10, 2025
All 20 articles loaded
Price Data
52-Week Range
$24.71
Fundamentals
Trading
About Septerna Inc
Septerna, Inc. is an innovative biotechnology company at the forefront of developing transformative therapeutics via selective protein modulation. With a commitment to addressing unmet medical needs across diverse disease areas, Septerna leverages proprietary platforms and deep scientific acumen to advance a robust pipeline of next-generation drug candidates. The company's strategic focus on research and development, coupled with its potential for significant clinical impact, positions it as a compelling opportunity for institutional investors seeking exposure in the dynamic biopharmaceutical sector.